These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26063813)

  • 1. Evaluation of antinuclear antibody (ANA) in ANA-associated connective tissue diseases.
    Lee AY; Hudspeth AR; Ray U
    J Clin Pathol; 2015 Oct; 68(10):853-4. PubMed ID: 26063813
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo antinuclear antibody of the skin: diagnostic significance and association with selective antinuclear antibodies.
    Velthuis PJ; Kater L; van der Tweel I; Meyling FG; Derksen RH; Hené RJ; van Geutselaar JA; Baart de la Faille H
    Ann Rheum Dis; 1990 Mar; 49(3):163-7. PubMed ID: 2181945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between antinuclear antibody titers and connective tissue diseases in a Rheumatology Department.
    Menor Almagro R; Rodríguez Gutiérrez JF; Martín-Martínez MA; Rodríguez Valls MJ; Aranda Valera C; de la Iglesia Salgado JL
    Reumatol Clin; 2017; 13(3):150-155. PubMed ID: 27221374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical utility of a positive antinuclear antibody test result.
    Abeles AM; Abeles M
    Am J Med; 2013 Apr; 126(4):342-8. PubMed ID: 23395534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding antinuclear antibodies.
    Pertusi RM; Rubin BR
    J Am Osteopath Assoc; 1991 Jun; 91(6):563-4, 567-9. PubMed ID: 1874653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological evaluation of in vivo epidermal nuclear fluorescence.
    Sousa JX; Miyamoto D; Zimbres JM; Costa DV; Aoki V
    Clin Exp Dermatol; 2009 Apr; 34(3):314-8. PubMed ID: 19040522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of substrates for the detection of antinuclear antibodies in normals and in patients with connective tissue and other diseases.
    Lipscomb MF; Cope LD; Stephens GL; Deng JS; Gilliam JN
    Diagn Immunol; 1984; 2(3):181-7. PubMed ID: 6388982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antinuclear antibodies appearing during PUVA therapy.
    Bruze M; Ljunggren B
    Acta Derm Venereol; 1985; 65(1):31-6. PubMed ID: 2578703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostic significance of antinuclear antibodies].
    Swaak AJ
    Ned Tijdschr Geneeskd; 2000 Mar; 144(13):585-9. PubMed ID: 10761543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical relevance of antinuclear antibodies in connective tissue diseases.
    Bombardieri S; Neri R; Tartarelli G; d'Ascanio A; Giovanelli L
    Scand J Rheumatol Suppl; 1987; 66():35-45. PubMed ID: 3502510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic value of antinuclear and anti-native-DNA antibodies in connective tissue diseases].
    Guzmán L; González C; Arriagada M; Grisanti M; Meléndez M; Arinoviche R
    Rev Med Chil; 1982 Jan; 110(1):24-8. PubMed ID: 6760312
    [No Abstract]   [Full Text] [Related]  

  • 12. [An immunoenzymatic technique for the detection of antinuclear antibodies].
    Meriche H; Meriche-Gadiri S; Ghaffor M; Abbadi MC
    Ann Biol Clin (Paris); 2000; 58(6):711-4. PubMed ID: 11098167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis.
    Szmyrka-Kaczmarek M; Pokryszko-Dragan A; Pawlik B; Gruszka E; Korman L; Podemski R; Wiland P; Szechinski J
    Lupus; 2012 Apr; 21(4):412-20. PubMed ID: 22074845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of antinuclear antibody connective tissue disease screen.
    López-Hoyos M; Rodríguez-Valverde V; Martinez-Taboada V
    Ann N Y Acad Sci; 2007 Aug; 1109():322-9. PubMed ID: 17785321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of positive antinuclear antibodies in individuals without connective tissue disease.
    Myckatyn SO; Russell AS
    J Rheumatol; 2003 Apr; 30(4):736-9. PubMed ID: 12672192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of antinuclear antibodies in connective tissue disease.
    Pahor A; Krajnc I; Gorenjak M; Holc I
    Wien Klin Wochenschr; 1998 May; 110(9):338-41. PubMed ID: 9629626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antinuclear antibodies in dermatology.
    Heffernan MP; Do JH; Mehta J
    Semin Cutan Med Surg; 2001 Mar; 20(1):2-13. PubMed ID: 11308133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay.
    Op De Beeck K; Vermeersch P; Verschueren P; Westhovens R; Mariën G; Blockmans D; Bossuyt X
    Autoimmun Rev; 2011 Oct; 10(12):801-8. PubMed ID: 21741497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of antinuclear antibodies and their fine specificities: time for a change in strategy?
    Otten HG; Brummelhuis WJ; Fritsch-Stork R; Leavis HL; Wisse BW; van Laar JM; Derksen RHWM
    Clin Exp Rheumatol; 2017; 35(3):462-470. PubMed ID: 28240588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic utility of unidentified precipitin lines (UPLs) in immune precipitation assays.
    Pajaro A; Nikoloutsopoulos T; Roberts-Thomson P
    Pathology; 2015 Jan; 47(1):62-7. PubMed ID: 25474508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.